Pre-existing SARS-2-specific T cells are predicted to cross-recognize BA.2.86

被引:11
|
作者
Sette, Alessandro [1 ,2 ]
Sidney, John [1 ]
Grifoni, Alba [1 ]
机构
[1] La Jolla Inst Immunol LJI, Ctr Vaccine Innovat, La Jolla, CA 92037 USA
[2] Univ Calif San Diego UCSD, Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92037 USA
基金
美国国家卫生研究院;
关键词
ESCAPE;
D O I
10.1016/j.chom.2023.11.010
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Effective monitoring of evolving SARS-CoV-2 variants requires understanding the potential effect of mutations on immune evasion. Here, we predicted the impact of BA.2.86-associated mutations on SARS-CoV-2-specific T cell responses. First, evaluating the effect on known experimentally defined T cell epitopes, we found that 72% and 89% of the total SARS-CoV-2 CD4 and CD8 responses were 100% conserved, with lower rates (56% and 72%) for just spike, a major structural protein. Among the mutated spike epitopes, however, 96% and 62% still bound the same reported HLA-restricting alleles. Additional prediction analyses comparing the ancestral and BA.2 sequences with BA.2.86 mutations identified several potentially novel BA.2.86 epitopes. By simulating exposure with BA.2, the large number of epitopes conserved with BA.2.86 suggests that variant-specific epitopes induced following breakthrough infection or bivalent vaccination can bridge the gap between ancestral immunization and upcoming circulating variants, allowing for a more stable T cell response across viral evolution.
引用
收藏
页码:19 / 24.e2
页数:9
相关论文
共 50 条
  • [31] Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3
    Liu, Yuanchen
    Zhao, Xiaoyu
    Shi, Jialu
    Wang, Yajie
    Liu, Huan
    Hu, Ye-Fan
    Hu, Bingjie
    Shuai, Huiping
    Yuen, Terrence Tsz-Tai
    Chai, Yue
    Liu, Feifei
    Gong, Hua-Rui
    Li, Jiayan
    Wang, Xun
    Jiang, Shujun
    Zhang, Xiang
    Zhang, Yanliang
    Li, Xiangnan
    Wang, Lei
    Hartnoll, Madeline
    Zhu, Tianrenzheng
    Hou, Yuxin
    Huang, Xiner
    Yoon, Chaemin
    Wang, Yang
    He, Yixin
    Zhou, Minmin
    Du, Lianzhao
    Zhang, Xiaojuan
    Chan, Wan-Mui
    Chen, Lin-Lei
    Cai, Jian-Piao
    Yuan, Shuofeng
    Zhou, Jie
    Huang, Jian-Dong
    Yuen, Kwok-Yung
    To, Kelvin Kai-Wang
    Chan, Jasper Fuk-Woo
    Zhang, Bao-Zhong
    Sun, Lei
    Wang, Pengfei
    Chu, Hin
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [32] Primary ChAdOx1 vaccination fails to reactivate pre-existing, cross-reactive T cells
    Henze, L.
    Braun, J.
    Meyer-Arndt, L.
    Juerchott, K.
    Schlotz, M.
    Michel, J.
    Grossegesse, M.
    Mangold, M.
    Dingeldey, M.
    Kruse, B.
    Holenya, P.
    Mages, N.
    Reimer, U.
    Eckey, M.
    Timmermann, B.
    Klein, F.
    Nitsche, A.
    Giesecke-Thiel, C.
    Loyal, L.
    Thiel, A.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 : 74 - 74
  • [33] Targeting neoantigens with immunotherapy: Are we limited to pre-existing autologous neoantigen-specific T-cells?
    Bracher, Aline
    Milosevic, Slavoljub
    Sommermeyer, Daniel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [34] Accumulation of type 2 cytokine+ T cells:: differentiation-independent proliferation of pre-existing type 2 T cells
    Loza, MJ
    Perussia, B
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (04) : 939 - 949
  • [35] Aging and CMV Infection Affect Pre-existing SARS-CoV-2-Reactive CD8+ T Cells in Unexposed Individuals
    Jo, Norihide
    Zhang, Rui
    Ueno, Hideki
    Yamamoto, Takuya
    Weiskopf, Daniela
    Nagao, Miki
    Yamanaka, Shinya
    Hamazaki, Yoko
    FRONTIERS IN AGING, 2021, 2
  • [36] Targeting of pre-existing and induced breast cancer stem cells with HER2-specific immunotherapeutics and NK cells
    Wischhusen, Joerg
    Diessner, Joachim
    Becker, Kathrin
    Hoenig, Arnd
    JOURNAL OF IMMUNOLOGY, 2011, 186
  • [37] SEPSIS DIFFERENTIALLY IMPACTS TUMOR-SPECIFIC VS. BYSTANDER T CELLS IN MICE WITH PRE-EXISTING MALIGNANCY
    Chen, Ching-wen
    Coopersmith, Craig
    Ford, Mandy
    SHOCK, 2018, 49 (06): : 21 - 21
  • [38] SARS CoV-2 infections in healthcare workers with a pre-existing T-cell response: a prospective cohort study
    Casado, Jose L.
    Haemmerle, Johannes
    Vizcarra, Pilar
    Velasco, Hector
    Velasco, Tamara
    Fernandez-Escribano, Marina
    Vallejo, Alejandro
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (06) : 916.e1 - 916.e4
  • [39] Human bone marrow hosts abundant pre-existing, SARS-CoV-2-reactive memory CD4+T cells in unexposed individuals
    Li, J.
    Reinke, S.
    Shen, Y.
    Schollmeryer, L.
    Liu, Y. -C.
    Hardt, S.
    Hipfl, C.
    Hoffmann, U.
    Frischbutter, S.
    Chang, H. -D.
    Alexander, T.
    Perka, C.
    Radbruch, H.
    Qin, Z.
    Radbruch, A.
    Dong, J.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 320 - 320
  • [40] Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses
    Tan, Cedric C. S.
    Owen, Christopher J.
    Tham, Christine Y. L.
    Bertoletti, Antonio
    van Dorp, Lucy
    Balloux, Francois
    INFECTION GENETICS AND EVOLUTION, 2021, 95